Rheumatoid arthritis (RA) is a chronic autoimmune disorder that leads to joint destruction and functional disability. Traditional treatments, including disease-modifying antirheumatic drugs (DMARDs), often fail, leaving many patients without remission. The advent of biologic therapies that target specific immune system components (e.g., cytokines, T cells) has transformed RA treatment by offering new management options. These biologics (e.g., TNF inhibitors, interleukin blockers) are highly effective in controlling disease activity and preventing joint destruction. However, their use comes with safety concerns, particularly regarding immunosuppression and infection risks. Although still experimental, studies predict that future research will focus on enhancing the clinical response and safety of these agents through personalized approaches or novel mechanisms of action.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592031PMC
http://dx.doi.org/10.7759/cureus.72486DOI Listing

Publication Analysis

Top Keywords

biologic therapies
8
rheumatoid arthritis
8
joint destruction
8
unlocking future
4
future biologic
4
therapies rheumatoid
4
arthritis rheumatoid
4
arthritis chronic
4
chronic autoimmune
4
autoimmune disorder
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!